Lifeward (LFWD) Net Income towards Common Stockholders (2015 - 2026)
Lifeward (LFWD) posted Net Income towards Common Stockholders of -$10.8 million for Q1 2026, down 101.81% sequentially from -$5.3 million in Q4 2025, and down 123.27% YoY from $46.4 million in Q1 2025.
Lifeward (LFWD) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
Lifeward has reported Net Income towards Common Stockholders for 12 years, with the latest figure at -$10.8 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 123.27% year-over-year to -$10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.9 million (up 5.92% YoY) and the FY2025 annual result came in at -$19.9 million, up 31.19% from the prior year.
- Net Income towards Common Stockholders slipped to -$10.8 million in Q1 2026 per LFWD's latest filing, from -$5.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$3.1 million in Q3 2024 and troughed at -$15.3 million in Q4 2024.
- A 5-year average of -$6.0 million and a median of -$5.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders sank 170.93% in 2024, then soared 65.0% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$5.3 million in 2022, then declined by 6.14% to -$5.6 million in 2023, then tumbled by 170.93% to -$15.3 million in 2024, then jumped by 65.0% to -$5.3 million in 2025, then plunged by 101.81% to -$10.8 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$10.8 million, -$5.3 million, and -$3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Lifeward | 20.56 Mn | 11.11 Mn | 2.71 Mn | -11.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.79 Mn |
| Dec 31, 2025 | -5.35 Mn |
| Sep 30, 2025 | -3.17 Mn |
| Jun 30, 2025 | -6.56 Mn |
| Mar 31, 2025 | -4.83 Mn |
| Dec 31, 2024 | -15.28 Mn |
| Sep 30, 2024 | -3.08 Mn |
| Jun 30, 2024 | -4.30 Mn |
| Mar 31, 2024 | -6.28 Mn |
| Dec 31, 2023 | -5.64 Mn |
| Sep 30, 2023 | -7.53 Mn |
| Jun 30, 2023 | -4.64 Mn |
| Mar 31, 2023 | -4.32 Mn |
| Dec 31, 2022 | -5.31 Mn |
| Sep 30, 2022 | -5.46 Mn |
| Jun 30, 2022 | -4.45 Mn |
| Mar 31, 2022 | -4.35 Mn |
| Dec 31, 2021 | -3.86 Mn |
| Sep 30, 2021 | -2.68 Mn |
| Jun 30, 2021 | -3.14 Mn |